Sarepta heading toward pivotal trial of first limb-girdle muscular dystrophy gene therapy

A new readout clears the path for Sarepta to move ahead next year with a pivotal study of its gene therapy for limb-girdle muscular dystrophy type 2E, one of several LGMD subtypes the company is seeking to treat.

The data also indirectly add to the body of evidence for the safety of

Read the full 513 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers